Additionally, other studies have shown that Trem2 knockout decreases atherosclerotic lesions.[40, 41] This raises concerns about using TREM2 as a therapeutic target in Alzheimer's disease, highlighting the need to avoid potential cardiovascular side effects of TREM2 agonist therapy. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.